Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Health Professional Version
SECTIONS
- General Information About Childhood Acute Myeloid Leukemia (AML)
- Classification of Pediatric Myeloid Malignancies
- Treatment Option Overview for Childhood AML
- Treatment of Childhood AML
- Acute Promyelocytic Leukemia (APL)
- Children With Down Syndrome and AML or Transient Abnormal Myelopoiesis (TAM)
- Myelodysplastic Syndromes (MDS)
- Therapy-Related AML/Myelodysplastic Syndromes
- Juvenile Myelomonocytic Leukemia (JMML)
- Chronic Myelogenous Leukemia (CML)
- Special Considerations for the Treatment of Children With Cancer
- Survivorship and Adverse Late Sequelae
- Changes to This Summary (10/23/2017)
- About This PDQ Summary
- View All Sections
Changes to This Summary (10/23/2017)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
This summary was comprehensively reviewed and extensively revised.
This summary was reformatted.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
.png)
No hay comentarios:
Publicar un comentario